Today: 29 April 2026
Browse Category

TSX:4519 8 July 2025 - 28 November 2025

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

Rani Therapeutics shares traded around $1.59 on 28 November, down from the previous close of $1.62 but still well above pre-October levels. No new press releases or SEC filings were issued today. The stock’s recent surge followed a major Chugai Pharmaceutical collaboration and $60.3 million private placement. Market cap stands near $190–200 million with roughly 97.5 million shares outstanding.
28 November 2025
··
Tokyo Stock Exchange Surges to Record Highs on AI Boom – Inside the Nov 3, 2025 Rally

Japan Stocks Today: Topix Closes at Record 3,359 as Nikkei Ends at 51,063; Sony’s Upgrade Offsets SoftBank Slump, Yen Nears ¥155

Topix closed at a record 3,359.33, up 1.14%, while the Nikkei 225 rose 0.43% to 51,063.31. SoftBank fell after confirming a $5.8 billion sale of its Nvidia stake; Sony jumped on an 8% profit forecast hike. The yen weakened near ¥155 per dollar. About 78% of Prime market stocks advanced.
12 November 2025
········
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics shares surged over 150% on Oct. 17, 2025, after announcing a collaboration and license deal with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in PIPE financing, stating it now has funding into 2028. Trading volume spiked to 70 million shares, up from a 300,000 average. Analyst opinions remain split on the stock’s outlook.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics shares surged nearly 190% to $1.37 on Oct. 17, 2025, after announcing a pharma partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal includes $10 million upfront, development and sales milestones, and potential royalties. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. Trading volume spiked to several times the daily average.
17 October 2025
···
The State of AI: Agentic Revolution, Healthcare Breakthroughs & Global Governance / Updated: 2025, July 8th, 12:00 CET

The State of AI: Agentic Revolution, Healthcare Breakthroughs & Global Governance / Updated: 2025, July 8th, 12:00 CET

More than 777 FDA-cleared AI devices are in clinical use for medical imaging in the U.S., cutting scan times and flagging urgent cases. Microsoft's MAI-DxO system reached 85.5% diagnostic accuracy, far above doctors at 20%. The U.S. Senate rejected a 10-year moratorium on state AI regulation. Meta recruited Apple’s Ruoming Pang for its AI push, while Wimbledon 2025 adopted AI-driven line calling amid player criticism.
8 July 2025
······

Stock Market Today

  • Verizon Shares Show Mixed Returns Amid Strong Long-Term Prospects
    April 28, 2026, 10:56 PM EDT. Verizon Communications (VZ) shares have delivered a 2.1% gain over the past week while declining 6.1% over 30 days, reflecting short-term volatility amid broader sector dynamics. Year-to-date and 12-month returns stand at 16.6% and 17.4% respectively, indicating stronger long-term performance. A discounted cash flow (DCF) model values Verizon shares at $134.19, significantly above the current price near $47.24, suggesting the stock is undervalued by approximately 65%. Verizon's role as a leading U.S. telecom provider and ongoing sector debates on infrastructure and competition continue to influence investor sentiment. The company holds a valuation score of 4 out of 6, highlighting mixed but generally positive financial metrics. Investors are advised to consider both short-term volatility and robust future cash flow projections when assessing Verizon's value.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop